Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19

Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19

Therapeutic options for coronaviruses remain limited. To address this unmet medical need, we screened 5406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactives, for activity against a South Korean Middle East respiratory syndrome coronavirus (MERS-CoV)...

Full description

Bibliographic Details
Main Authors: Meehyun Ko, So Young Chang, Soo Young Byun, Aleksandr Ianevski, Inhee Choi, Anne-Laure Pham Hung d’Alexandry d’Orengiani, Erlend Ravlo, Wei Wang, Magnar Bjørås, Denis E. Kainov, David Shum, Ji-Young Min, Marc P. Windisch
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Viruses
Subjects:
Middle East respiratory syndrome coronavirus
severe acute respiratory syndrome coronavirus disease
clinical isolate
high-content screening
FDA-approved drugs
drug repurposing
Online Access:https://www.mdpi.com/1999-4915/13/4/651

Internet

https://www.mdpi.com/1999-4915/13/4/651

Similar Items